drugset / Trial / NCT00759824
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary aim of this study is to determine if the addition of valproic acid to a combination of adriamycin, cyclophosphamide and vindesine could increase progression-free survival in patients relapsing after first-line chemotherapy including platinum derivatives, cisplatin or carboplatin, and etoposide.
Timeline
- Start
- 2008-09
- Primary completion
- 2013-12
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valproic Acid | Small molecule | 20 mg/kg | Oral |
| Subject | Valproic Acid | Small molecule | 30 mg/kg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 1 g | Intravenous |
| Background | Doxorubicin | Other / unclassified | 45 mg/m2 | Intravenous |
| Background | Vindesine | Small molecule | 3 mg/m2 | Intravenous |